Metformin Hydrochlorid Eg (Eurogenerics) (Metformin Hydrochloride)

Metformin Hydrochloride is employed in the management of type 2 diabetes mellitus, a disorder of glucose metabolism.

• Type 2 diabetes mellitus: improves overall glycemic control by lowering fasting and post‑prandial blood glucose.
• Adjunct therapy in type 2 diabetes: added when diet, exercise and lifestyle measures alone are insufficient.
• First‑line monotherapy for type 2 diabetes: can be initiated as the initial oral agent in newly diagnosed patients.

• Metformin Hydrochloride acts primarily by inhibiting hepatic gluconeogenesis, thereby reducing hepatic glucose output. It also decreases intestinal absorption of glucose and enhances peripheral insulin sensitivity, facilitating increased glucose uptake by muscle and adipose tissue. These combined actions lower circulating blood glucose levels without stimulating insulin secretion.

Metformin Hydrochloride may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare but serious events require prompt medical attention.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: frequent loose stools.
• Abdominal discomfort: cramping or pain.
• Metallic taste: transient alteration in taste perception.
• Weight loss: modest reduction in body weight.
• Loss of appetite: decreased desire to eat.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening buildup of lactic acid.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Hypoglycemia: uncommon when used alone but possible with other glucose‑lowering agents.
• Vitamin B12 deficiency: long‑term therapy may reduce B12 absorption.

Metformin Hydrochloride requires careful consideration of patient‑specific factors and monitoring to minimize risks.

• Renal function: assess creatinine clearance before initiating and periodically thereafter.
• Hepatic impairment: avoid use in patients with significant liver disease.
• Risk of lactic acidosis: discontinue before any radiographic contrast procedures.
• Vitamin B12 monitoring: consider periodic assessment during long‑term therapy.
• Contraindications: do not use in patients with known hypersensitivity to metformin.
• Store below 25°C: keep in the original packaging, protect from moisture and heat.

Metformin Hydrochloride can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate lactic acidosis; withhold metformin before and after the procedure.
• Cimetidine: can increase metformin plasma concentrations, raising the risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Alcohol: excessive intake may potentiate lactic acidosis.
• Diuretics (loop or thiazide): may affect renal function and increase metformin accumulation.
• Warfarin: may require closer INR monitoring due to potential interaction.